home / stock / omga / omga quote
Last: | $1.89 |
---|---|
Change Percent: | 0.0% |
Open: | $2.09 |
Close: | $1.89 |
High: | $2.12 |
Low: | $1.89 |
Volume: | 513,143 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.89 | $2.09 | $1.89 | $2.12 | $1.89 | 513,143 | 07-04-2024 |
$1.89 | $2.09 | $1.89 | $2.12 | $1.89 | 513,143 | 07-03-2024 |
$2.07 | $2.21 | $2.07 | $2.22 | $2.06 | 326,308 | 07-02-2024 |
$2.25 | $2.11 | $2.25 | $2.26 | $2.06 | 754,565 | 07-01-2024 |
$2.07 | $2.27 | $2.07 | $2.3271 | $2.07 | 3,160,100 | 06-28-2024 |
$2.24 | $2.37 | $2.24 | $2.37 | $2.17 | 650,128 | 06-27-2024 |
$2.35 | $2.4 | $2.35 | $2.625 | $2.3 | 607,658 | 06-26-2024 |
$2.4 | $2.4 | $2.4 | $2.4191 | $2.31 | 332,307 | 06-25-2024 |
$2.42 | $2.35 | $2.42 | $2.5 | $2.29 | 507,491 | 06-24-2024 |
$2.43 | $2.25 | $2.43 | $2.44 | $2.21 | 775,754 | 06-21-2024 |
$2.2 | $2.2 | $2.2 | $2.24 | $2.07 | 600,803 | 06-20-2024 |
$2.22 | $2.05 | $2.22 | $2.4099 | $1.91 | 1,525,238 | 06-19-2024 |
$2.22 | $2.05 | $2.22 | $2.4099 | $1.91 | 1,525,238 | 06-18-2024 |
$1.86 | $2 | $1.86 | $2.0093 | $1.85 | 372,752 | 06-17-2024 |
$2.03 | $2.1 | $2.03 | $2.1 | $1.94 | 286,359 | 06-14-2024 |
$2.1 | $2.09 | $2.1 | $2.105 | $2.01 | 150,767 | 06-13-2024 |
$2.11 | $2.18 | $2.11 | $2.22 | $2.09 | 416,807 | 06-12-2024 |
$2.14 | $2.1 | $2.14 | $2.2 | $1.99 | 738,529 | 06-11-2024 |
$2.12 | $2.02 | $2.12 | $2.14 | $1.96 | 295,709 | 06-10-2024 |
$2 | $2 | $2 | $2.08 | $1.96 | 309,841 | 06-07-2024 |
News, Short Squeeze, Breakout and More Instantly...
Omega Therapeutics Inc. Company Name:
OMGA Stock Symbol:
NASDAQ Market:
Omega Therapeutics Inc. Website:
CAMBRIDGE, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the election of Richard N. Kender to its...
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in fires...
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the appointment of Kaan Certel, Ph.D., as...